About AOD peptide
AOD peptide is an independent reading project built around one compound. The premise is that a narrow, well-cited page is more useful to a researcher than a broad catalogue, and that a site which never sells anything has no reason to soften a caveat. The substantive material lives on the preclinical research and molecular overview; this page explains how that material is assembled and checked.
There is no commercial relationship behind the site. No supplier is listed, no affiliate arrangement exists, and no listing is accepted in exchange for placement. That constraint is not a stylistic choice: it removes the incentive to present an unverified claim as though it were settled.
What We Publish
Chemistry first: sequence, disulfide connectivity, molecular formula and mass, and the physical form in which research material is supplied. Then mechanism as it has been characterised in vitro and in animals, with the model named for each observation. Then the formulation literature, including what is actually known about oral and troche formats as opposed to what is asserted about them. Finally, the limitations of all of it, stated on the same page rather than in a footnote.
What We Do Not Publish
No human dosing, no administration schedules, no preparation protocols. No outcome claims. No vendor rankings, no purchasing guidance, no commercial comparison. No coverage of other peptides, which would dilute both the terminology and the evidence. Where the laboratory-handling section discusses units and arithmetic, it does so in the abstract and says explicitly that it is not a protocol.
How Sources Are Traced
Each substantive claim is tied to a public record, principally PubMed and NCBI entries, and the citation list is kept to sources a reader can open and check. Where a figure appears in more than one publication with different values, the range is reported rather than a single preferred number. Where the underlying work is a conference abstract or a secondary summary, that is stated instead of being presented as a peer-reviewed finding.
Attribution is grammatical as well as bibliographic. A finding is written as 'the authors reported' or 'in the model used', never as a general property of the molecule. This is the single most common failure in secondary writing about research peptides, and correcting it is most of the editorial work here. The research limitations section shows the same discipline applied to absence of evidence.
Corrections and Updates
Pages are reviewed on a rolling basis and the review date is shown on the research page. A correction is made in place, and where the correction changes a figure or a cited conclusion the change is noted in the review line rather than silently applied. Readers who spot an error can reach the editorial team through the contact link in the footer.
Research enquiry about this summary? The editorial team answers questions about sources, terminology and coverage.
Message us